# US 8,278,453 B2 · Quinolizidinone M1 receptor positive allosteric modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,453 B2
- Document ID: US8278453B2
- Status: Granted
- Kind: B2
- Application number: 13/121,423
- Filed: 2009-09-29
- Published: 2011-07-21
- Granted: 2012-10-02
- Earliest claimed: 2008-10-06
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Scott D. Kuduk; Christina Ng Di Marco
- Web page: https://patentgrep.com/patent/US8278453B2

## CPC

- C07D 455/02: containing not further condensed quinolizine ring systems
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to quinolizidinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

## Claims

### Claim 1

A compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein
X is N or CH, and
Y is N or CH, provided that both X and Y are not N;
Q is selected from the group consisting of
(1) —CH2—,
R1 is selected from the group consisting of
(1) hydrogen,
(2) —C1-6 alkyl, or
(3) —CH2-aryl,
wherein said R1 alkyl or aryl moiety is optionally substituted with one or more
(a) halogen,
(b) cyano, and
(c) —O—C1-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen;
R2 is selected from the group consisting of
(2) heteroaryl, wherein said heteroaryl is a cyclic or polycyclic aromatic ring system having from four to twelve ring atoms, said ring atoms selected from C, CH, C═O, N or O,
(3) —C6-10 aryl,
wherein the aryl or heteroaryl ring is optionally substituted with one or more
(a) —C1-6 alkyl,
(b) —OC1-6 alkyl,
(c) —C6-10 aryl, or
(d) halogen;
and provided that at least one of X, Y, or R2 contains a nitrogen atom.

### Claim 2 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen.

### Claim 3 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X and Y are both CH.

### Claim 4 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is N and Y is CH.

### Claim 5 (depends on 1)

A compound of any of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is heteroaryl.

### Claim 6 (depends on 5)

A compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein R2 is a 5- or 6-membered heteroaryl ring having one or two nitrogen ring atoms, wherein the remainder of the ring atoms are carbon.

### Claim 7 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is aryl.

### Claim 8 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is halogen.

### Claim 9 (depends on 1)

A compound of claim 1, which is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
